For
Genetic information reveals innate or familial traits rather than choices people make, so using it in underwriting can feel like punishing people for their biology and relatives. A ban treats genetic predisposition more like protected status than voluntary risk-taking.
If people fear higher premiums or denial of cover after a test, they may avoid testing even when it would help with prevention, diagnosis, or family planning, and that can delay screening or treatment in ways that worsen health outcomes. That creates a public-health cost beyond the insurance contract.
Many variants do not determine outcomes, and the same result may have different implications depending on environment, treatment, ancestry, and family history. This weakens the case for individualized pricing based on genetics.
People should not face worse access to essential financial protection because of inherited risk. Prohibiting genetic underwriting can spread rare but severe risks across a broader pool rather than concentrating them on a small number of families.
If insurers may use some genetic data but not others, rules become complex, contestable, and difficult for consumers to monitor. A bright-line ban reduces disputes and improves trust in the market.